ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
05/04/201617:34:13Statement of Changes in Beneficial Ownership (4)
05/04/201617:32:27Statement of Changes in Beneficial Ownership (4)
05/04/201617:28:32Statement of Changes in Beneficial Ownership (4)
05/04/201617:25:54Statement of Changes in Beneficial Ownership (4)
05/04/201617:25:02Statement of Changes in Beneficial Ownership (4)
05/04/201617:14:36Initial Statement of Beneficial Ownership (3)
05/03/201607:00:00Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer...
05/03/201607:00:00Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer...
05/02/201613:34:00Ackman: No Plans to Sell Any Valeant `Crown Jewel' Assets -CNBC
04/30/201603:03:00Valeant Default Fears 'Cured' -- WSJ
04/30/201603:03:00Sequoia Reopens To New Clients -- WSJ
04/29/201618:01:00Valeant Holder Sequoia Fund Reopens to New Investors -- 2nd Update
04/29/201617:31:00Valeant Holder Sequoia Fund Reopens to New Investors -- Update
04/29/201616:51:19Additional Proxy Soliciting Materials (definitive) (defa14a)
04/29/201613:30:00Valeant Files Overdue Annual Report, Makes Sweeping Board Changes--Update
04/29/201612:43:00Valeant Files Overdue Annual Report, Makes Sweeping Board Changes--Update
04/29/201612:20:00Valeant Holder Sequoia Fund Reopens to New Investors
04/29/201611:06:36Proxy Statement (definitive) (def 14a)
04/29/201610:15:00Valeant Files Overdue Annual Report, Makes Sweeping Board Changes--Update
04/29/201609:31:00Valeant Announces Nominees For Election To Board Of Directors

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad